PARP Inhibitors in the Treatment of Ovarian Cancer
Introduction Ovarian cancer is a leading cause of cancer mortality globally due to late-stage diagnosis and limited treatment options. PARP inhibitors have shown promise as effective treatments for recurrent and various stages of ovarian cancer. Aim of the Study This study reviews the eff...
Saved in:
Main Authors: | Andrzej Paweł Zuzak, Magdalena Cieślik-Porębska, Krzysztof Kułak, Jagoda Niewiadomska |
---|---|
Format: | Article |
Language: | English |
Published: |
Kazimierz Wielki University
2025-02-01
|
Series: | Journal of Education, Health and Sport |
Subjects: | |
Online Access: | https://apcz.umk.pl/JEHS/article/view/57677 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PARP inhibitors in the treatment of Pancreatic Cancer - A Review of literature
by: Jagoda Niewiadomska, et al.
Published: (2025-01-01) -
Repression of PFKFB3 sensitizes ovarian cancer to PARP inhibitors by impairing homologous recombination repair
by: Yinan Xiao, et al.
Published: (2025-01-01) -
Editorial: Ovarian cancer targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more, volume II
by: Zhi-Bin Wang, et al.
Published: (2025-02-01) -
Poly-ADP ribose polymerase (PARP) inhibitor regimens for platinum-sensitive ovarian cancer in randomized, double-blind, phase III controlled trials: protocol for a systematic review and network meta-analysis
by: Xiaolian Peng, et al.
Published: (2025-01-01) -
Simultaneously delivery of functional gallium ions and hydrogen sulfide to endow potentiated treatment efficacy in chemo- and PARPi-resistant ovarian cancer
by: Sangsang Tang, et al.
Published: (2025-02-01)